ACTRN12619000317190Recruiting未知
Clinical Trial examining the sensitivity and specificity of Gazefinder for identifying young children with autism
a Trobe University0 sites200 target enrollmentStarted: March 1, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 24 Months to 59 Months (—)
- Sex
- All
Inclusion Criteria
- •Children with autism: Aged between 2 years 0 months and 4 years 11 months, with diagnosis of autism from a community professional (evidenced through provision of copy of report/letter).
- •Typically Developing (TD) children: Aged between 2 years 0 months and 4 years 11 months
Exclusion Criteria
- •Children with autism: Uncorrected visual/hearing impairment
- •Typically developing (TD) children: Uncorrected visual/hearing; parent-reported family history of autism among first-degree relatives (parent/s and/or sibling/s); presence of another developmental condition and/or moderate-level autism behaviours (operationalised as score >12 on Social Communication Questionnaire).
Investigators
Similar Trials
Recruiting
Phase 2
Sensitivity and specificity of three-point compression ultrasonography in diagnosis of deep vein thrombosisDeep vein thrombosis.Phlebitis and thrombophlebitis of other deep vessels of lower extremitiesIRCT20190309042978N1Sari University of Medical Sciences70
Completed
Phase 2
CHAMP: Clearing High Risk HPV Among Men who have sex with Men PilotACTRN12617001355369The Alfred31
Completed
Not Applicable
Clinical Trial for evaluation of the clinical effect of on line hemodiafiltration (HDF) and beta2-microglobulin adsorption column combination therapy.JPRN-UMIN000009429Hyogo College of Medicine40
Completed
Phase 2
Clinical study to investigate safety, tolerability, efficacy,pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD– A randomised, double-blind, parallel group, multicenter, phase IIa pilot study –J44.9Chronic obstructive pulmonary disease, unspecifiedDRKS00006087Philipps-Universität Marburg19
Active, not recruiting
Not Applicable
Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild allergic asthmaEUCTR2012-003570-77-DEsterna biologicals GmbH & Co. KG